{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Food and Drug Administration Accelerated Approval of Lecanemab for Early Alzheimer's Disease - Hope, Reality, and the Unknown Going Forward

Activity Steps

1 Activity
2 Take Test 3Certificate

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Select the appropriate interventions for patients who have early Alzheimer's disease.
  2. Recognize the potential and actual therapeutic action of lecanemab.
  3. Identify the reported adverse effects of lecanemab.

Learning Outcomes

Seventy-five percent of participants will demonstrate competency in clinical reasoning regarding the state of the science in understanding and treating Alzheimer's disease, including a new drug that targets the disorder's pathophysiology, by achieving a minimum score of 70% on the outcomes-based posttest.

Disclosures

The author and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity.

Price: $17.95

Credits:

  • ANCC 1.5 CH / 1.5 APH
  • DC - BON 1.5 CH
  • FL - BON 1.5 CH
  • GA - BON 1.5 CH
  • NM - BON 1.5 CH
  • SC - BON 1.5 CH
  • WV - BOERN 1.5 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.

Awarded Advanced Pharmacology Hours













Planner
Test Code: CNS0523
Published: May/Jun 2023
Expires: 6/6/2025
Sources: Clinical Nurse Specialist: The Journal for Advanced Nursing Practice
Required Passing Score: 8/10 (80%)
Authors: Patricia Anne O'Malley, PhD, APRN-CNS
Categories: Advanced Pharmacology Hours , Advanced Practice Nursing , Geriatrics , Neurological
Specialties: Advanced Practice Nursing, Gerontology, Neurology
Topics: Alzheimer Disease , Drug Update